Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1085548

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1085548

Ragweed Pollen Allergy Treatment Market, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

Ragweed pollen is considered as one of the most common roots of seasonal allergies, especially in the U.S. The pollen present in ragweed plants is the main cause of this disease. These plants are found in 17 different types of species in North America. An autoimmune response is generated in ragweed allergy affected population. The immune cells of affected patients produces chemicals to combat the pollen considering it as a foreign substance. This reaction leads to various irritating symptoms, such as itchy eyes, running nose, and sneezing. However, these symptoms or allergy can be treated with allergy shots and medications.

Global Ragweed Pollen Allergy Treatment Market Dynamics

The increasing number clinical trials and development of novel treatment and therapies are the major factors boosting the growth of global ragweed pollen allergy treatment market. Moreover, the increasing pollution and changing environmental conditions are other factors propelling the market growth. For instance, according to the Asthma and Allergy Foundation of America (AAFA), in 2018, about 75% of people who are allergic to pollen are also allergic to ragweed. An individual who is allergic to one type of pollen, tends to develop allergies to other types of pollen as well.

Moreover, the rising number of approvals of ragweed pollen allergy treatment is expected to drive the overall market growth. For instance, Novartis AG received U.S. FDA approval for Xolair for the treatment of mild to severe persistent pollen allergy treatment in September 2018. Since the initial approval of Xolair, more than 330,000 Americans aged 12 years and older have been treated with pollen allergy and allergic asthma.

However, the lack of awareness related to allergy immunotherapy (AIT) and high cost of the treatment are some of the major factors restricting the growth of global ragweed pollen allergy treatment market.

Key features of the study:

  • This report provides in-depth analysis of the global ragweed pollen allergy treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunity across different segments and explains the attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global ragweed pollen allergy treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
  • Key players covered as a part of this study are ALK-Abello A/S, ASIT Biotech SA, Anergis SA, Biomay AG, and Astellas Pharma Inc., Thermo Fisher Scientific Inc, Siemens Healthcare Private Limited, Omega Diagnostics Group PLC, Stallergenes Greer, bioMerieux SA, Lincoln Diagnostics, Inc, HOB Biotech Group Corp Ltd, HYCOR Biomedical, Inc, Alcon, Hitachi Chemical Diagnostics, Inc, Quest Diagnostics Incorporated, Circassia, Immunomic Therapeutics, Inc, Novartis AG, Japan Tobacco Inc, GlaxoSmithKline plc, REGiMMUNE Co, Ltd, Sanofi, and Merck KGaA.
  • Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future drug launches, governmental initiatives, technological advancements, geographical expansion, and marketing tactics
  • The global ragweed pollen allergy treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the ragweed pollen allergy treatment market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Ragweed Pollen Allergy Treatment Market, By Drug Class:
    • Antihistamines
    • Decongestants
    • Nasal Corticosteroids
    • Others
  • Global Ragweed Pollen Allergy Treatment Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Channel
  • Global Ragweed Pollen Allergy Treatment Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drug Class:
    • Antihistamines
    • Decongestants
    • Nasal Corticosteroids
    • Others
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Channel
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drug Class:
    • Antihistamines
    • Decongestants
    • Nasal Corticosteroids
    • Others
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Channel
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drug Class:
    • Antihistamines
    • Decongestants
    • Nasal Corticosteroids
    • Others
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Channel
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drug Class:
    • Antihistamines
    • Decongestants
    • Nasal Corticosteroids
    • Others
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Channel
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drug Class:
    • Antihistamines
    • Decongestants
    • Nasal Corticosteroids
    • Others
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Channel
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
      • By Drug Class:
    • Antihistamines
    • Decongestants
    • Nasal Corticosteroids
    • Others
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Channel
  • Company Profiles
    • ALK-Abello A/S
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • ASIT Biotech SA
    • Anergis SA
    • Biomay AG
    • Astellas Pharma Inc.
    • Thermo Fisher Scientific Inc
    • Siemens Healthcare Private Limited
    • Omega Diagnostics Group PLC
    • Stallergenes Greer
    • bioMerieux SA
    • Lincoln Diagnostics, Inc
    • HOB Biotech Group Corp Ltd
    • HYCOR Biomedical, Inc
    • Alcon
    • Hitachi Chemical Diagnostics, Inc
    • Quest Diagnostics Incorporated
    • Circassia
    • Immunomic Therapeutics, Inc
    • Novartis AG
    • Japan Tobacco Inc
    • GlaxoSmithKline plc
    • REGiMMUNE Co, Ltd
    • Sanofi
    • Merck KGaA.

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI4054

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Technological Advancements in Ragweed Pollen Allergy Treatment
  • Need for Ragweed Pollen Allergy Treatment
  • Recommendations and guidelines by regulatory bodies
  • Key Developments
  • Acquisition, Collaborations & Partnerships
  • Epidemiology
  • PEST Analysis

4. Global Ragweed Pollen Allergy Treatment Market, Impact of Coronavirus (Covid-19) Pandemic

  • Pre COVID-19 Market Scenario
  • Post COVID-19 Market Scenario
  • Strategies

5. Global Ragweed Pollen Allergy Treatment Market, By Drug Class, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Antihistamines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Decongestants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Nasal Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Ragweed Pollen Allergy Treatment Market, By Distribution Channel, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Online Channel
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Ragweed Pollen Allergy Treatment Market, By Region, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • ALK-Abello A/S
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • ASIT Biotech SA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Anergis SA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Biomay AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Astellas Pharma Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!